Good morning,
Welcome to today's edition of The Armchair Analyst, a 5-minute daily update on the ASX life-sciences sector.
Yesterday afternoon, I finished up at the Digital Health Festival in Melbourne.
My head full of ideas, and my pockets full of single-use mentos packets.
If you've been to any trade show, you know the ones. Dangerous.
AI was the buzzword of the conference.
But I don't think AI tells the whole story.
It is change management.
Healthcare institutions face massive switching costs when changing systems.
Some still use fax machines for patient records.
Some still use phone calls to track hospital beds.
The cracks are showing, and the systems are under enormous pressure…
But how do you actually convince a hospital to upgrade its systems?
I came across one framework that I think might help:
Growth = Demand × Trust × Conversion × Measurement.
If the product ticks all boxes, then it is set up for success.
But drop off in one, it’s an uphill battle.
But first…
The Pulse Check
Avecho Biotechnology (ASX: AVE) completed the treatment phase for 244 participants in its pivotal Phase III insomnia trial. Interim analysis on track for late June 2026.
🪑 Crunch time now.
Here is my bull/bear/base case.
Bear case: Interim results show the treatment isn't working. The trial stops. Avecho has to go back to the drawing board. This will be bad.
Bull case: Interim results indicate the treatment is working, but additional patient data is needed to complete registration. The trial continues with an additional 319 patients at more sites. Full results likely sometime in mid-to-late 2028.
Mega-bull case: The interim results are so strong that the trial can be stopped early and called complete. Avecho receives the US$16 million milestone payment from Sandoz. The company moves straight to registration, potentially putting a product on shelves far sooner than anyone expected.
My full take on the trial 👉 Don’t sleep on this one: The Avecho Story (ASX: AVE)
Argenica Therapeutics (ASX: AGN) successfully completes the second of three FDA-requested mouse studies to advance its IND application toward Phase 2b trial approval. (AGN)
🪑 Milestone ticked.
Island Pharmaceuticals (ASX: ILA) appoints former BioCryst executive Raymond Taylor as a Senior Scientific Fellow to advance its anti-viral drug Galidesivir. (ILA)
🪑 Nice appointment. Raymond will be incredibly familiar with Galadisivir, given his time at BioCryst, where the drug was purchased.
Adherium (ASX: ADR) announces a 100-to-1 share consolidation. (ADR)
Little Green Pharma (ASX: LGP) reports FY26 revenue up 15.3% to $42.5M, while swinging to a $1.4M net loss from FY25 profit of $3.3M. (LGP)
Cash Injection
TruScreen Group (ASX: TRU) announces a trading halt ahead of a capital raising to secure up to NZ$2.9M. (TRU)
Under the Microscope
Betting on a technology that services the healthcare system is all about sales.
What is the value proposition, and what are the barriers to selling?
Sales are sticky.
Which is good if you’re in.
… but hard to get there.
So, at the 2026 Digital Health Festival, I wanted to answer one question…
How do ASX-listed health tech stocks actually sell into large institutions?
Healthcare institutions face massive switching costs when changing systems.
Any change to a business should expect a 20% “decrease” in performance to start (potentially more depending on how impactful the change is).
That makes the hurdle rate for doing anything new at least 20% for it to be worth it…
… and arguably 40%, 50%, or even 100%.
This happens because changing anything leads to an immediate drop in performance.
Pain now for gain later…
OR continue with business as usual.
This is the challenge facing ASX-listed tech companies selling into the healthcare system.
The solution needs to be so good that it BEATS the time, effort, and the immediate performance drop required to make a change.
If you look through the AI facade that was pasted all over the conference, change management was the real talking point.
Here are all the panel discussions on the topic… (just from one stage)
There were a number of ASX-listed companies that I went to visit here:
Alcidion (ASX: ALC) - a workflow management solution for hospitals.
Oneview Healthcare (ASX: ONE) - a patient experience platform for hospitals.
(Here is the new setup with the MyChart bedside by EPIC, a deal signed just last week)
Visionflex (ASX: VFX) - a product that provides virtual care for rural and remote areas.
Tiny market cap, this one at $5 million - but an interesting product when you understand the value proposition.
The challenge for each of these companies is: how do you change a system?
How do you sell the product when you know the change will be painful?
I was typing out yesterday's article near one of the speaker stages, half-listening to the session running behind me, and I realised the speaker was laying out the exact framework I'd been looking for.
Growth = Demand × Trust × Conversion × Measurement.
The session, titled “Why Growth Stalls”, by Ellie Baker, discusses sales of technology products into healthcare systems.
Not a medical device. Where there are clinical guidelines and reimbursements to anchor to.
Not a drug. Where there is a defined patient population.
Technology systems. Tools to improve a healthcare system that has been doing things the same way since before the fax machine.
This framework landed for me because it was a multiplication.
Growth = Demand × Trust × Conversion × Measurement.
If any of these drop off. Growth stalls.
Demand: Is there a real pain point, or is this a solution looking for a problem?
Trust: Does the product have clinical credibility, references, and case studies?
Conversion: Are your customers actually using it once they've bought it?
Measurement: What's the one number that makes the buyer impossible to ignore?
Products that nail all four should be in the best position to sell.
Innovators lead the way, but the mainstream market is where the money is made
While the conference was a hotbed of excitement about AI and the future of healthcare technology… here’s the reality.
Those at the conference only represent a small slice of the healthcare system.
The early innovators at the very top of the technology curve.
But how do you penetrate the late majority? The laggards? The people who weren't anywhere near the Melbourne Convention Centre this week?
I thought a lot about this, too, and I think I have some answers.
FIRST, Time.
Educating the market on the value proposition takes time.
But it is not just educating the market on the value proposition…
It is about getting the customer (in this case, a hospital) comfortable with taking a 20% hit to productivity in pursuit of an outsized productivity gain.
Sales cycles for hospitals are measured in years, not quarters.
The Oneview sales rep told me that some of the deals they are landing now stem from conversations that started over two years ago.
But once you’re in, you’re in.
SECOND, Traction.
Sometimes the product is just that good, and the market moves faster than anyone expected.
This is what is happening with AI right now, and one company in particular: Heidi.
Heidi is a private startup that sells an AI scribe that sits in on consultations, listens to the conversation, and spits out a clinical note.
The company did a Series A round 2 years ago for $10M.
Last October, the company raised US$65 million at a US$465 million valuation.
Genuine hockey stick growth in two years…
And it is what penetration looks like when the product solves a pain point.
(Yep, hockey stick growth can happen in the healthcare system)
What Heidi got right is that it could sell to the individual doctor. Not the healthcare system.
This meant that it could penetrate the tech enthusiasts first and then go to a hospital and say:
65% of your doctors are already using our product. Do you want to roll it out throughout the rest of the hospital?
This type of organic traction makes those big, chunky sales cycles a lot smoother because hospitals don’t need to guess at value. They already know.
THIRD, Sometimes, they just won't get there.
This is the reality.
A portion of the healthcare ecosystem will never adopt the technology.
The regional GP clinic where the principal partner has handwritten notes for generations.
The 70+-year-old specialist has been using the same tools for over 40 years.
There will be laggards in every industry.
Eventually, new clinics will emerge that do use technology and will compete away these businesses.
Maybe the specialist will sell, and the next person will roll out technology.
It’s an incredibly slow process for the industry to change like this, but it is the last shoe to drop.
So selling to the late majority is all about being patient.
It’s about showing up at conferences, educating the market, and hoping the product gains enough traction for sales to flow smoothly.
The Armchair Take
While AI was the buzzword of the conference. AI doesn’t tell the story.
The real challenge still sits around change management for large institutions that have been doing things the same way for a very long time.
AI doesn't fix that. AI just makes the next conversation easier.
But the tide is turning.
And it all stems back to the fundamental question…
Will someone buy?
And will someone go through the pain of changing to get an improvement on the other side?
This is the equation to work out that answer:
Growth = Demand × Trust × Conversion × Measurement.
See you tomorrow,
The Armchair Analyst
